PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
Manuel Rodrigues(Inserm), Sophie Piperno‐Neumann(Institut Curie), Pascale Mariani(Université Paris Sciences et Lettres), Clémentine Bouchez, Grégoire Marret(Université Paris-Saclay), Mathilde Saint‐Ghislain(Centre Oscar Lambret), Leanne de Koning(Université Paris Sciences et Lettres), R. Sanchez(Institut Curie), Véronique Gillon(Institut Curie), Zahra Ajgal(Institut Curie), Sandra Nespoulous(Institut Curie), Toulsie Ramtohul(Université Paris Sciences et Lettres), Elsa Lafite(Institut Curie), Vincent Servois(Université Paris Sciences et Lettres)
Cited by 2
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869